Answers are grounded in this paper and cite their sources.
Introduction/Objective Oral colchicine is associated with gastrointestinal adverse effects and limited therapeutic tolerability. This study aimed to develop a colchicine- Nigella sativa oil-loaded nanoemulgel and evaluate its dermal permeation and anti-inflammatory efficacy. Methods Formulation of a nanoemulgel based on colchicine (2% w/w) and N. sativa oil (8% w/w) was done via the spontaneous emulsification method. Stability of the formulation, globule size, drug and excipient interactions, and skin permeation studies were assessed. The anti-inflammatory activity of the formulation was assessed via the carrageenan-induced paw edema model in which 36 rats were used in six different groups. Results The optimized nanoemulgel formulation showed a globule size of 152.6 ± 3.1 nm, and its stability was observed up to 3 months. In the case of the formulation, there was a remarkable reduction in paw oedema to 28.6 ± 1.9% at 4 hours ( p < 0.001), showing a 71.4% anti-edema effect. The values of cumulative permeation, flux, apparent permeability coefficient, and skin deposition were 62.9 µg/cm 2 , 2.53 µg/cm 2 /h, 3.76 × 10 −5 cm/s, and 28.7 µg/cm 2 , respectively. Discussion The enhanced anti-inflammatory activity and dermal penetration indicate synergistic effects in the action of colchicine and N. sativa oil, indicating the therapeutic potential of this drug combination. Conclusion The colchicine- N. sativa nanoemulgel demonstrated enhanced dermal delivery and significant anti-inflammatory activity in an experimental rat model. Further investigations are required to establish clinical efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Jahan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: